NEW EUROPEAN, COMMUNITY CO-CREATED SURVEY REVEALS STRONG INTEREST IN LONG-ACTING HIV TREATMENT OPTIONS BUT REPORTED IN-CLINIC CONVERSATIONS LAG BEHIND

London, 29 July 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new data revealing a gap between interest in long-acting HIV treatment options and the conversations taking place in clinics. The data also highlight inequities in whether long-acting treatment is being discussed during consultations across different demographic groups of people living with HIV in Europe. These findings highlight the need for more proactive, equitable care that ensures people can access options aligned to their needs and preferences.

The data come from Ask Us Europe, a community co-produced online survey of more than 1,900 people living with HIV across 18 European countries. Results were presented at the 26^th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. 

Long-acting HIV treatment conversations are not reaching everyone equally

An equity analysis from the survey showed conversations about long-acting injectable Vocabria + Rekambys (cabotegravir + rilpivirine (CAB+RPV LA)) and treatment review discussions varied across social and demographic groups, including by age, ethnicity, education and time since diagnosis.¹

• Among participants who had had a treatment optimisation discussion with their healthcare provider (81% (n=1549/1911)), only 45% (n=558/1246) reported that they had discussed CAB+RPV LA.
• 19% (n=362/1911) of respondents said they did not ever recall having a treatment review discussion.
• Respondents aged over 55 years were less likely to have discussed CAB+RPV LA with their healthcare provider than those under the age of 55.
• These findings show the need for more proactive and equitable conversations in clinic, so people living with HIV can understand the treatment options available to them.

Strong interest in long-acting HIV treatment options

Further data from the survey revealed strong interest in CAB+RPV LA and potential future long-acting HIV treatment options, with greatest interest in future injectables dosed two or three times a year.²

• 93% (n=1,656/1,782) of respondents expressed interest in future long-acting treatment modalities, with the highest interest in injectables dosed two or three times a year (77% (n=1,371).
• 68% (n=1,207) expressed interest in monthly orals, and 56% (n=1,000) in weekly orals, while implants (40% (n=721)) and patches (34% (n=604)) were the least favoured.
• Among those who had ever received CAB+RPV LA, 89% (n=250/282) were interested in future long-acting injectables dosed two or three times a year, while only 20% (n=56) expressed interest in weekly oral options.
• These findings underscore the importance of developing a range of treatment options that reflect different preferences and needs of people living with HIV.   

About Vocabria (cabotegravir)

Vocabria injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class.

Vocabria tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:

• oral lead-in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long-acting rilpivirine injection.
• oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection.

Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant (rilpivirine) tablets should also be consulted for recommended dosing.

Please consult the full Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injection and Vocabria 30 mg film-coated tablets

About the Ask Us Europe Study

The Ask Us Europe study is an equity-focused, co-produced, mixed-methods study from the SHARE Collaborative in partnership with 18 community members, the European AIDS Treatment Group (EATG) and the UK Community Advisory Board (UK-CAB). The study was designed to capture the real-world perspectives and experiences of people living with HIV on antiretroviral therapy, with a focus on treatment discussions, access to innovation and support needs. Between July 2025 and January 2026, 1,825 people living with HIV completed the online survey across 18 European countries and languages, recruited via social media and community/ clinical networks. The study is led by Principal Investigator Professor Chloe Orkin and is funded by ViiV Healthcare. For more information, please visit: shareresearch.org.uk/ask-us-study/.